| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
MINNEAPOLIS, November 5, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients wi... |
| 21 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On behalf of CVRx, Inc. (“CVRx” or the “Company”), I am pleased to offer you employment with CVRx. Subject to fulfillment of the conditions of employment mentioned in this letter, your estimated hire date will be October 12, 2026, pendin... |
| 11 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
MINNEAPOLIS, August 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients wit... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
MINNEAPOLIS, August 6, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... |
| 09 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
I want to thank you for your service to CVRx, Inc. (the “Company”). I understand you have chosen to transition from CVRx and appreciate your willingness to effect a smooth transition as outlined in this letter agreement (“Agreement”). |
| 03 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 1, 2026, CVRx, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). Voting results for each matter submitted to a vote at the Annual Meeting are provided below. |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
MINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with c... |
| 13 Apr 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025 |
| 03 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
CVRx, Inc. (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), hereby grants an Award of Performance Stock Units (“PSUs”) to you, the Participant named below. The terms and conditions of this Award are set forth in ... |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with ... |
| 12 Jan 2026 |
8-K: Entry into a Material Definitive Agreement
CVRx, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Comp... |
| 12 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of January 9, 2026, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
MINNEAPOLIS, November 5, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients wi... |
| 04 Aug 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
MINNEAPOLIS, August 4, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... |
| 05 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 3, 2025, CVRx, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). Voting results for each matter submitted to a vote at the Annual Meeting are provided below. |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
MINNEAPOLIS, May 8, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with ca... |
| 07 Apr 2025 |
8-K: Results of Operations and Financial Condition
First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 |
| 04 Feb 2025 |
8-K: Results of Operations and Financial Condition
MINNEAPOLIS, Feb. 4, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular d... |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35% |
| 04 Nov 2024 |
8-K: Other Events
On November 4, 2024, CVRx, Inc. (the “Company”) announced that the Centers for Medicare and Medicaid Services assigned the Barostim procedure to New Technology Ambulatory Payment Classification (APC) 1580. The APC payment of approximatel... |
Loading...